Literature DB >> 12635936

Helicobacter pylori infection: CagA-specific antibodies are associated with clinical outcome, but not with HLA-class II polymorphisms of the host.

Erdmute Kunstmann1, Cornelia Hardt, Jean E Crabtree, Sebastian Suerbaum, Jörg T Epplen.   

Abstract

In order to investigate the interrelation between immunogenetic host and bacterial factors the T-cell receptor (TCR) polymorphism TCRBV6S1 A/B, HLA-DRB1 alleles and cagA status was analyzed in 380 unrelated German individuals. H. pylori infection with cagA-positive bacterial strains was significantly associated with peptic ulcer disease in the German cohort. Patients homozygous for the non-functional TCRBV6S1B allele and presenting with peptic ulcer disease showed no CagA-specific antibodies in the majority of cases. There was no association between HLA-DRB1 alleles and the CagA status of infected individuals, although certain alleles show significant association to the infection status in different populations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12635936     DOI: 10.1078/1438-4221-00237

Source DB:  PubMed          Journal:  Int J Med Microbiol        ISSN: 1438-4221            Impact factor:   3.473


  3 in total

1.  CagA in Barrett's oesophagus in Colombia, a country with a high prevalence of gastric cancer.

Authors:  M Kudo; O Gutierrez; H M T El-Zimaity; H Cardona; Z Z Nurgalieva; J Wu; D Y Graham
Journal:  J Clin Pathol       Date:  2005-03       Impact factor: 3.411

2.  Real time high resolution magnetic resonance imaging for the assessment of gastric motility disorders.

Authors:  W Ajaj; S C Goehde; N Papanikolaou; G Holtmann; S G Ruehm; J F Debatin; T C Lauenstein
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

3.  The Prevalence Rate of Helicobacter pylori Infection in, Chronic Otitis Media With Effusion Patients.

Authors:  Nader Saki; Ali Reza Samarbaf Zadeh; Reza Sheikhpour Jonaky; Seyed Mahdi Noori; Gholam Abbas Kayedani; Soheila Nikakhlagh
Journal:  Jundishapur J Microbiol       Date:  2014-03-01       Impact factor: 0.747

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.